Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major Wilson disease markets reached a value of US$ 317.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 428.2 Million by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

The Wilson disease market has been comprehensively analyzed in IMARC's new report titled "Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Wilson disease is a rare genetic disorder that causes copper to accumulate in the body, particularly in the liver, brain, and eyes. The condition is caused by a mutation in the ATP7B gene, which is responsible for regulating the body's copper metabolism. The symptoms of this ailment include fatigue, lack of appetite, abdominal pain, yellowish whites of the eye, golden-brown eye discoloration, fluid buildup in the legs or abdomen, difficulty with speech, swallowing, or physical coordination, uncontrolled movements, muscle stiffness, etc. Individuals suffering from Wilson disease may also experience psychiatric problems like depression and anxiety. The diagnosis of this illness relies on an evaluation of the patient's symptoms, medical history, and eye examination using a slit lamp. The healthcare provider may also perform various diagnostic tests and procedures, including blood workups, urinalysis, genetic testing, etc., to determine the possible causes of underlying indications.

The increasing cases of autosomal recessive disorder, causing gene variations and chromosomal abnormalities, are primarily driving the Wilson disease market. In addition to this, the widespread adoption of copper chelation therapy with trientine and penicillamine to reduce copper levels in blood and prevent further organ damage is also propelling the market growth. Moreover, numerous pharmaceutical companies are focusing on developing effective heavy metal toxicity medications with a lower frequency of side effects and higher bioavailability. This, in turn, is acting as a significant growth-inducing factor. Additionally, the inflating demand for zinc acetate in maintenance therapy that can prevent the absorption of copper into the bloodstream from food, thereby prohibiting excessive copper buildup, is further creating a positive outlook for the market. Apart from this, the emerging popularity of anion exchange chromatography-triple quadrupole coupled with mass spectrometry for simple ceruloplasmin quantification and more accurate determination of copper levels in the body is positively influencing the market growth. Moreover, the ongoing developments in gene therapy using adeno-associated vectors, which can transduce both quiescent and replicating cell population, are expected to drive the Wilson disease in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Wilson disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Wilson disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Wilson disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Wilson disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Wilson disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Wilson disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Wilson disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Wilson disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Wilson disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Wilson disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Wilson disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Wilson disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Wilson disease across the seven major markets?
What is the size of the Wilson disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Wilson disease?
What will be the growth rate of patients across the seven major markets?

Wilson Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Wilson disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wilson disease market?
What are the key regulatory events related to the Wilson disease market?
What is the structure of clinical trial landscape by status related to the Wilson disease market?
What is the structure of clinical trial landscape by phase related to the Wilson disease market?
What is the structure of clinical trial landscape by route of administration related to the Wilson disease market? Show more